Holen Sie sich die Stockscreener-App
19.28
2.68%
-0.53
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$19.81
Offen:
$19.71
24-Stunden-Volumen:
934.85K
Relative Volume:
0.66
Marktkapitalisierung:
$1.37B
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-9.2249
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
-4.98%
1M Leistung:
-11.36%
6M Leistung:
-54.58%
1J Leistung:
-45.55%
1-Tages-Spanne:
$18.87
$19.71
1-Wochen-Bereich:
$18.87
$21.15
52-Wochen-Spanne:
$17.64
$53.69
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Vergleichen Sie TNDM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
19.28 | 1.37B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
130.82 | 226.88B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
99.36 | 146.96B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
364.50 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.63 | 112.37B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.91 | 41.85B | 5.72B | 4.17B | 259.90M | 6.97 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Artificial Pancreas Device System Market Projected To Witness - openPR
Tandem Diabetes Care Insiders Sell US$1.5m Of Stock, Possibly Signalling Caution - Simply Wall St
Tandem Diabetes Care Inc (TNDM) Stock Price Down 4.6% on Mar 26 - GuruFocus.com
3 Reasons to Sell TNDM and 1 Stock to Buy Instead - Yahoo Finance
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology - MSN
Stifel maintains Tandem Diabetes Care stock Buy rating, $60 target By Investing.com - Investing.com UK
(TNDM) Long Term Investment Analysis - Stock Traders Daily
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock? - MSN
Tandem Diabetes at Oppenheimer Conference: Strategic Growth Insights - Investing.com
Tandem Diabetes at Oppenheimer Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Tandem announces publication of results from trial of Control-IQ+ AID technology - Yahoo Finance
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data - Yahoo Finance
Tandem’s Control-IQ+ looks like a smart move for insulin-using T2D - BioWorld Online
Tandem reports A1C reduction in type 2 diabetes study By Investing.com - Investing.com South Africa
Tandem Diabetes Launches Next-Gen Automated Insulin Delivery Algorithm in U.S. - MPO-mag
Tandem reports A1C reduction in type 2 diabetes study - Investing.com India
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes - Business Wire
Automated Insulin Delivery System Helps in Type 2 Diabetes - Medscape
Tubeless Insulin Pump Market Is Booming Worldwide | Medtronic - openPR
Tandem Diabetes Care launches Control-IQ+ automated insulin delivery technology in the US - Marketscreener.com
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States - Enid News & Eagle
3 Healthcare Stocks Walking a Fine Line - Yahoo Finance
Artificial Pancreas (Closed-Loop Insulin Delivery) Market - openPR
Tandem Diabetes Care (NASDAQ:TNDM) Trading Up 6.1% Following Insider Buying Activity - Defense World
Here's What Key Metrics Tell Us About Tandem Diabetes Care (TNDM) Q4 Earnings - MSN
Tandem Diabetes at Leerink Conference: Strategic Growth Amid Challenges By Investing.com - Investing.com UK
Victory Capital Management Inc. Decreases Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Bank of New York Mellon Corp Purchases 4,130 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Tandem Diabetes Care’s SWOT analysis: stock outlook amid market challenges - Investing.com
Keybank National Association OH Has $245,000 Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Tandem Diabetes EVP Kyrillos purchases $190,966 in company stock By Investing.com - Investing.com South Africa
Tandem Diabetes EVP Kyrillos purchases $190,966 in company stock - Investing.com
Reasons to Hold TNDM Stock in Your Portfolio for Now - Nasdaq
Tandem Diabetes Care: A Buy Rating Backed by Growth Potential and Valuation Opportunity - TipRanks
Smartleaf Asset Management LLC Acquires 1,101 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Tandem Diabetes Care, Inc. to Host Earnings Call - ACCESS Newswire
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by US Bancorp DE - Defense World
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Oppenheimer & Co. Inc. - Defense World
TANDEM DIABETES CARE, INC. (NASDAQ:TNDM) DEADLINE ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Tandem Diabetes Care, Inc. - ACCESS Newswire
Tandem Diabetes Care stock hits 52-week low at $18.27 By Investing.com - Investing.com Australia
Tandem Diabetes Care stock hits 52-week low at $18.27 - Investing.com
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Position Increased by Private Advisor Group LLC - Defense World
Morgan Stanley Downgrades Tandem Diabetes Care (NASDAQ:TNDM) to Equal Weight - Defense World
Tandem Diabetes Care (NASDAQ:TNDM) Rating Lowered to Neutral at Citigroup - Defense World
Morgan Stanley Downgrades Tandem Diabetes Care (TNDM) - MSN
Tandem Diabetes Care downgraded to Equal-weight on guidance concerns - MSN
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tandem Diabetes Care Inc-Aktie (TNDM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Carpenter Rick | Chief Technology Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
406 |
0 |
16,538 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer |
Mar 07 '25 |
Buy |
18.12 |
10,538 |
190,966 |
10,538 |
| Morrison Susan | EVP & Chief Admin. Officer |
Feb 25 '25 |
Option Exercise |
0.00 |
6,903 |
0 |
32,821 |
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER |
Feb 25 '25 |
Option Exercise |
0.00 |
6,903 |
0 |
29,252 |
| Gasser Elizabeth Anne | EVP, Chief Strategy Officer |
Feb 25 '25 |
Option Exercise |
0.00 |
6,903 |
0 |
10,032 |
| Sheridan John F | PRESIDENT & CEO |
Feb 25 '25 |
Option Exercise |
0.00 |
32,779 |
0 |
89,017 |
| Gasser Elizabeth Anne | EVP, Chief Strategy Officer |
Feb 18 '25 |
Option Exercise |
0.00 |
2,141 |
0 |
4,754 |
| Hansen Shannon Marie | EVP & Chief Legal Officer |
Feb 18 '25 |
Option Exercise |
0.00 |
1,969 |
0 |
13,253 |
| Morrison Susan | EVP & Chief Admin. Officer |
Feb 18 '25 |
Option Exercise |
0.00 |
2,141 |
0 |
26,823 |
| Sheridan John F | PRESIDENT & CEO |
Feb 18 '25 |
Option Exercise |
0.00 |
8,502 |
0 |
61,754 |
0.55%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):